Crizotinib in the treatment of non-small-cell lung cancer

Patrick M. Forde, Charles M. Rudin

Research output: Contribution to journalReview articlepeer-review

Abstract

Introduction: Recent progress in identifying distinct subsets of lung cancer, based on critical driver mutations, has led to increasingly focused efforts in the development of selectively targeted therapies. The fusion oncogene, echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK), is present in approximately 5% of non-small-cell lung cancer (NSCLC) tumors. Crizotinib is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK. Emerging data suggest that crizotinib may also have activity in other subsets of lung cancer, including tumors demonstrating amplification or mutation of the MET oncogene, or translocation of the ROS1 oncogene. Areas covered: This paper gives an overview of the molecular pathogenesis of ALK-associated NSCLC. It also reviews the pharmacokinetic and pharmacodynamic data on crizotinib and outlines the preclinical and clinical studies leading to the approval of crizotinib. In addition, it discusses its role in the treatment of NSCLC expressing ALK. Expert opinion: Crizotinib represents the newest example of a focused strategy for drug development in lung cancer, based on identification and targeted inhibition of critical tumor-specific driver mutations. Crizotinib has demonstrated efficacy against ALK-rearranged NSCLC, and has potential for broader application in select subsets of lung cancer.

Original languageEnglish (US)
Pages (from-to)1195-1201
Number of pages7
JournalExpert opinion on pharmacotherapy
Volume13
Issue number8
DOIs
StatePublished - Jun 1 2012

Keywords

  • Anaplastic lymphoma kinase
  • Crizotinib
  • EML4-ALK
  • Fusion gene
  • Non-small-cell lung cancer
  • Targeted therapy
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Crizotinib in the treatment of non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this